A Phase 1, Randomized, Double-Blind, Third-Party-Unblinded Trial to Evaluate the Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (20vPnC) and 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Pneumococcal Vaccine-Naïve Adults 50 Years of Age and Older in China

This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China. The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC in Chinese adults 50 years of age and older who did not receive any of pneumococcal vaccine in the past

开始日期2025-07-06

申办/合作机构

Pfizer Inc.

CTR20252347

/ Active, not recruiting临床1期

一项在未接种过肺炎球菌疫苗的 ≥ 50 岁中国成人中评价 20 价肺炎球菌多糖结合疫苗 (20vPnC) 和 13 价肺炎球菌多糖结合疫苗 (13vPnC) 的安全性和免疫原性的随机、双盲、第三方非盲I 期临床试验

主要目的：描述 20vPnC 和 13vPnC 的安全性特征次要目的：描述 20vPnC 和 13vPnC 诱导的免疫应答

开始日期2025-07-06

申办/合作机构

辉瑞投资有限公司

[+4]

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的临床结果

登录后查看更多信息

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的转化医学

登录后查看更多信息

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的专利（医药）

登录后查看更多信息

1,246

项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的文献（医药）

2025-12-31·Expert Review of Vaccines

Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China

Article

作者: Wang, Chaofan ; Zhang, Haijun ; Lai, Xiaozhen ; Deloria Knoll, Maria ; Wahl, Brian ; Zhang, Haonan ; Fang, Hai

BACKGROUND:

The burden of pneumococcal disease varies regionally in China, disproportionately affecting children in many provinces such as Qinghai and Hainan. Nevertheless, the absence of a pneumococcal conjugate vaccine (PCV) in the National Immunization Program (NIP) or local programs presents limited coverage. This study evaluated the health and economic impact of including PCV in immunization programs in Qinghai and Hainan.

RESEARCH DESIGN AND METHODS:

A decision tree Markov model was constructed to simulate health outcomes and lifetime costs among children under different 13-valent PCV (PCV13) vaccination strategies compared to current practices, from societal and healthcare perspectives. Data on epidemiology, vaccine efficacy, cost, and utility were obtained from the literature and open databases. Sensitivity analyses were conducted to explore parameter uncertainty.

RESULTS:

Including three-dose PCV13 in provincial programs at NIP coverage (98.91%) could avert 7100 episodes and 118 deaths in Qinghai, and 6200 episodes and 66 deaths in Hainan. It was cost-effective at the $68.2/dose in private market and cost-saving at the United Nations Children's Fund (UNICEF) recommended $25/dose for both provinces. Increasing coverage to 50% or 75% was also cost-effective. Sensitivity analyses confirmed the robustness of the results despite parameter uncertainty.

CONCLUSIONS:

Prioritizing PCV13 in immunization programs in Qinghai and Hainan could effectively reduce disease burden, improve population health, and promote health equity.

2025-12-31·Human Vaccines & Immunotherapeutics

Multidimensional analysis of costs and outcomes in a Colombian cohort of pediatric Streptococcus pneumoniae meningitis cases (2017–2022)

Article

作者: Londoño-Ruiz, Juan Pablo ; Coronell Rodríguez, Wilfrido ; Restrepo Cedeño, Alejandro ; Álvarez-Olmos, Martha I. ; López, Pio ; Suarez, Martha Alexandra ; Rojas Hernández, Juan Pablo ; Vasquez-Hoyos, Pablo ; Ramos Rodriguez, Nicolas I. ; Trujillo Honeysberg, Mónica Rosa ; Beltrán-Higuera, Sandra J. ; Barrero Barreto, Esther Rocio ; Mariño, Ana Cristina ; Lucia Leal, Aura ; Arango Ferreira, Catalina ; Patiño, Jaime Alberto ; Giraldo Gallo, Erika ; Gutiérrez-Tobar, Ivan Felipe ; David Escobar Franco, Omar Huang ; Montañez Ayala, Anita ; López Medina, Eduardo ; Espinosa Acuña, Fabio Enrique ; Camacho-Moreno, German ; Castro Montoya, Bibiana ; Moreno, Vivian Marcela

Streptococcus pneumoniae meningitis poses a significant public health challenge, imposing substantial burdens on healthcare systems. This study analyzed the costs and outcomes of pneumococcal meningitis in a Colombian cohort of children from 2017 to 2022, using correspondence analysis and cost assessment to explore the impact of vaccination. A retrospective cohort study was conducted, analyzing children under 18 years diagnosed with pneumococcal meningitis. A total of 55 cases were analyzed in this cohort study, which, while representative of confirmed cases in the country, reflects the rarity of the disease and poses statistical limitations. Direct healthcare costs were calculated in 2023 USD, and data were assessed using cluster and multiple correspondence analyses (MCA) to evaluate relationships between vaccination status, serotypes, clinical outcomes, and costs. The MCA revealed two main dimensions that collectively explained 31.2% of the total variance. Median direct healthcare costs were ~$2,900 (range ~$500-$21,000), with ICU admission as the primary cost driver. PCV13 vaccination correlated with lower overall patient costs and better clinical outcomes. MCA revealed clustering of vaccinated patients with favorable outcomes and reduced costs, while unvaccinated patients aligned with severe outcomes and higher expenses. This study explores the clinical and economic impact of pneumococcal meningitis in pediatric patients, highlighting the potential protective role of PCV13 vaccination. MCA provided an exploratory framework for examining relationships between vaccination status, serotypes, costs, and outcomes.

2025-12-31·Human Vaccines & Immunotherapeutics

The microbiological characteristics and diagnosis of Streptococcus pneumoniae infection in the conjugate vaccine era

Review

作者: Tsai, Ming-Han ; Chen, Chih-Jung ; Chen, Chih-Ho ; Chen, Chyi-Liang ; Su, Lin-Hui ; Chiu, Cheng-Hsun

Two pneumococcal conjugate vaccines, PCV15 and PCV20, were licensed in June 2021. PCV15 includes two additional serotypes (22F, 33F) beyond those in PCV13, while PCV20 adds seven more (8, 10A, 11A, 12F, 15B, 22F, 33F), covering approximately 30% of invasive pneumococcal disease (IPD) cases in adults. In June 2023, the US CDC's Advisory Committee on Immunization Practices (ACIP) recommended either PCV15 or PCV20 for all children aged < 5 years and children aged 2‒18 years with risk conditions. In June 2024, the FDA approved PCV21 for adults ≥ 18 years. In October 2024, ACIP recommended either PCV20 or PCV21 alone or PCV15 with PPSV23 for adults ≥ 50 years or 19-49 years with risk conditions. These advancements highlight the evolving landscape of pneumococcal vaccination. This review examines the molecular epidemiology of pneumococcal infections, advancements in diagnostic methods, and the anticipated public health impact of these vaccines in reducing pneumococcal disease burden.

183

项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的新闻（医药）

2025-10-13

·Business Wire

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from company- and collaborator-led studies will showcase significant advancements in preventing and treating infectious diseases. “IDWeek 2025 offers a critical opportunity to highlight our cutting-edge scientific progress and collaborate with global health experts in our ongoing battle against infectious diseases,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer. “At Pfizer, we continue to prioritize innovation and rigorous data generation through clinical studies and real-world analysis supporting the vaccines and therapeutics for our infectious disease pipeline.” Presentations will include research from Pfizer’s diverse infectious disease portfolio, including COVID-19, respiratory syncytial virus (RSV), pneumococcal disease, Lyme disease, meningococcal disease, and other serious bacterial and viral infections. Details for the oral and poster presentations are below: Title/Abstract Number Presenting Name/Type Date/Time (ET) Location ORAL & LATE-BREAKING PRESENTATIONS Attitudes about COVID and Community Engagement with Patients (ACCEPt): Global Survey Reveals the Ongoing Impact of Long COVID-19 on Medically Vulnerable Populations, Five Years On R Paredes Oct 22 4:15 – 4:30PM B211-B212 Effectiveness of the JN.1-adapted BNT162b2 COVID-19 Vaccine in High-Risk Groups against Hospitalization in Europe: A Test-Negative Case-Control using the id.DRIVE Platform H Volkman Oct 21 1:45 – 3:00PM B401-B402 Real-world Abrysvo Vaccine Effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related Lower Respiratory Tract Disease (LRTD) Hospitalizations and Emergency Department Admissions over Two RSV Seasons—Kaiser Permanente of Southern California (KPSC), October 2023–April 2025 S Tartof Oct 20 3:15 – 4:30PM B401-B402 Immunosuppression and RSV Prefusion F Protein Vaccine Effectiveness in Older Adults: A Prespecified sub analysis from the DAN-RSV Trial A Jensen Oct 20 3:15 – 4:30PM B401-B402 POSTER PRESENTATIONS COVID-19 COVID-19 vaccine uptake in children aged 1 - 4 years from state vaccine registry data through March 2024 T Ahi Oct 22 12:15 PM Poster Hall B4-5 Public Health and Economic Impact of Increased Uptake of an Additional Dose of Pfizer-BioNTech KP.2-Adapted COVID-19 Vaccine, 2024-2025 Formula, Among US Adults ≥ 65 Years of Age A Yehoshua 12:15 PM Poster Hall B4-5 Physician Perceptions and Decision-Making Factors in Prescribing COVID-19 Antivirals: Qualitative Research Findings M Fernandez 12:15 PM Poster Hall B4-5 Ibuzatrelvir Potently Reduced Viral RNA Levels Despite the High Rate of Anti-S Seropositivity: a Post Hoc Analysis of Serology in the Phase 2b Study in Adults Without Risk Factors for Severe COVID-19 JH Kim 12:15 PM Poster Hall B4-5 Inpatient Burden of Respiratory Syncytial Virus, COVID-19, or Influenza in the United States Among Children < 5 Years of Age K Andersen 12:15 PM Poster Hall B4-5 Severity of Omicron COVID-19 variants: a global systematic literature review D Malhotra 12:15 PM Poster Hall B4-5 COVID-19 Case Attack Rate Differences by Vaccination Status and Vaccine Effectiveness among US Nursing Home Residents, October 5, 2024 to January 5, 2025 F Khan 12:15 PM Poster Hall B4-5 Invasive Group B Streptococcus (GBS) Invasive Group B Streptococcus among hospitalized pregnant and postpartum women, 2016-2024: a Unites States database study S Willis 12:15 PM Poster Hall B4-5 Long-Term Healthcare Utilization and Expenditures for Infants with Invasive Bacterial Infections During Birth Hospitalizations K Schley 12:15 PM Poster Hall B4-5 Lyme Disease Risk Perception and Communication about Lyme Disease Prevention by Healthcare providers: A Mixed-Methods Study N Patel 12:15 PM Poster Hall B4-5 Gestational Lyme disease incidence and pregnancy-related outcomes among women in the United States, 2015-2024 S Willis 12:15 PM Poster Hall B4-5 Healthcare Costs Associated With Lyme Disease Among Medicare Fee-for-Service Beneficiaries in the United States: A Retrospective Claims-Based Study H Yu 12:15 PM Poster Hall B4-5 Meningococcal Disease Need for Broad Protection Against Invasive Meningococcal Disease Among US College Students J Presa 12:15 PM Poster Hall B4-5 Characterization of Factor H Binding Protein Expression for Neisseria meningitidis Serogroup B Isolates, 2015–2022 K Weiss 12:15 PM Poster Hall B4-5 Clinical Development of MenABCWY (PenbrayaTM), a Broadly Protective Pentavalent Meningococcal Vaccine L Zoloras 12:15 PM Poster Hall B4-5 Utility of the Pentavalent MenABCWY Meningococcal Vaccine (PenbrayaTM) Within Alternative US Meningococcal Vaccination Schedules J Presa 12:15 PM Poster Hall B4-5 Ten-year retrospective review of medical records at five hospitals in the United States highlights the potential for under-detection of invasive meningococcal disease F Angulo 12:15 PM Poster Hall B4-5 Awareness, Attitudes and Perceptions of Meningococcal Vaccines among Caregivers of Adolescents in the United States J Presa 12:15 PM Poster Hall B4-5 Pneumococcal Disease Re-evaluating economic & health impact of PCV20 in adults using real-world effectiveness data J Vietri 12:15 PM Poster Hall B4-5 Invasive pneumococcal pneumonia: is bacteremia the appropriate indication of severity? P Peyrani 12:15 PM Poster Hall B4-5 Variability in Case-Ascertainment Methodology and Rates of Adult Invasive Pneumococcal Disease using a US Healthcare Claims Database A Miles 12:15 PM Poster Hall B4-5 Temporal Trends in Rates of Hospitalized Pneumonia among US Adults and Residual Disparities by Race and Socioeconomic Status A Miles 12:15 PM Poster Hall B4-5 Demographic and Clinical Characteristics, by Pneumococcal Serotype, of Adults Hospitalized with Community Acquired Pneumonia in the US L Grant 12:15 PM Poster Hall B4-5 Differences in invasive pneumococcal disease clinical presentations and serotype distribution among children with and without underlying risk factors K Hulten 12:15 PM Poster Hall B4-5 Nasopharyngeal Colonization in South Texas Children Less Than 6 Years of Age With or Without Lower Respiratory Tract Infections K Hulten 12:15 PM Poster Hall B4-5 Real-world effectiveness of 20-valent pneumococcal conjugate vaccine among adults 65-74, 75-84, and ≥85 years of age in the United States A Miles 12:15 PM Poster Hall B4-5 Uptake and Series Completion with Pneumococcal Conjugate Vaccine by Social Determinants of Health among Children in the United States A Miles 12:15 PM Poster Hall B4-5 Influenza Symptom Burden During the First Week of Acute Influenza Infection Among US Adults: An Interim Analysis of a Nationwide Prospective Study during the 2024/25 Season T Hu 12:15 PM Poster Hall B4-5 The Burden of Influenza on Health-Related Quality of Life and Work Productivity During the First Week of infection Among US Adults: An Interim Analysis of a Nationwide Prospective Study T Hu 12:15 PM Poster Hall B4-5 The Socioeconomic Value of Adult Respiratory Vaccination in the United States: A Benefit-Cost Analysis T Hu 12:15 PM Poster Hall B4-5 Respiratory Syncytial Virus (RSV) How do recent population-level RSVpreF vaccine impact results from the United Kingdom relate to previously reported vaccine effectiveness results? N Aliabadi 12:15 PM Poster Hall B4-5 Bivalent RSV Prefusion F-Based Subunit Vaccine Recipients with Chronic Kidney Disease Achieved High Neutralizing Titers One Month After Vaccination F Rahman 12:15 PM Poster Hall B4-5 Immunogenicity and Safety of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Non-Pregnant HIV Infected Older Adults T Mikati 12:15 PM Poster Hall B4-5 Estimating Risk of Guillain-Barré Syndrome in US Medicare-Enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-Controlled Case Series Analysis C Liang 12:15 PM Poster Hall B4-5 Time to Testing, Diagnosis, and Hospitalization Among Pediatric and Adult Patients with RSV in Two Seasons: A Real-World Data Analysis using Electronic Health Records in US W Tang 12:15 PM Poster Hall B4-5 Time-Series Model Estimation of RSV-Attributable Respiratory Hospitalizations and Mortality in Adults in Finland C Liang 12:15 PM Poster Hall B4-5 Burden of Hospitalizations Due to Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age and Those with Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations A Tippett 12:15 PM Poster Hall B4-5 What if Adult RSV Vaccine Uptake in the US was High Like in Scotland? Missed Opportunities to Reduce Public Health and Economic Burden of RSV R Sato 12:15 PM Poster Hall B4-5 Strategies to promote adult vaccination against respiratory pathogens: a narrative literature review E Williams 12:15 PM Poster Hall B4-5 Attributes of Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus (RSV): Results of a Systematic Literature Review K Date 12:15 PM Poster Hall B4-5 RSV Signs and Symptoms at Time of Hospitalization among Pediatric and Adult Population with RSV in Two Seasons: A Real-World Data Analysis using Electronic Health Records in US W Tang 12:15 PM Poster Hall B4-5 Tick-Borne Encephalitis (TBE) Tick-borne encephalitis (TBE) in international travelers and TBE vaccine recommendations for travelers to Europe F Angulo 12:15 PM Poster Hall B4-5 Prescribing Information for Pfizer Medicines Please see full Prescribing Information for ABRYSVO® (Respiratory Syncytial Virus Vaccine) or visit https://abrysvoadult.pfizerpro.com. Please see full Prescribing Information for COMIRNATY® (COVID-19 Vaccine, mRNA) or visit https://comirnatyhcp.com. Please see full Prescribing Information including BOXED WARNING for PAXLOVIDTM (Nirmatrelvir and Ritonavir) or visit https://paxlovid.pfizerpro.com. Please see full Prescribing Information for PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine) or visit https://prevnar20.pfizerpro.com. Please see full Prescribing Information for PREVNAR 13® (Pneumococcal 13-valent Conjugate Vaccine). Please see full Prescribing Information for PENBRAYA® (Meningococcal Groups A, B, C, W, and Y Vaccine) or visit https://penbraya.pfizerpro.com. Please see full Prescribing Information for TRUMENBA® (Meningococcal Group B Vaccine) or visit https://trumenba.pfizerpro.com. Please see full Prescribing Information for TICOVAC™. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. DISCLOSURE NOTICE: The information contained in this release is as of October 13, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about Pfizer’s infectious disease pipeline, in-line products and product candidates, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risk and uncertainties include, among other things, uncertainties regarding the commercial success of Pfizer’s infectious disease products and product candidates; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim and preliminary data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any drug applications, biologics license applications and/or emergency use authorization applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s products or product candidates, including development of products or therapies by other companies; manufacturing capabilities or capacity; risks and uncertainties related to changes to vaccine or other healthcare policy in the U.S.; uncertainties regarding the ability to obtain or maintain recommendations from vaccine advisory or technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations, including uncertainties related to the potential impact of narrowing recommended patient populations; challenges related to public vaccine confidence or awareness; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

疫苗临床结果临床2期

2025-10-13

·生物制品圈

2025 老年人疫苗新进展，这 5 种病防护要更新！

摘要:咱们身边 65 岁以上的长辈越来越多了 ——2025 年数据显示，欧盟 65 岁以上人口已占 21.3%，80 岁以上的人未来 75 年还会增加 2.5 倍。但老年人的免疫系统会随年龄变弱（也就是 “免疫衰老”），普通疫苗效果打折扣，一旦感染流感、肺炎这些病，不仅容易住院，还可能留下走路没劲、记忆力下降的 “长期后遗症”，甚至增加心脏病、中风的风险。好消息是，2025 年最新研究里，老年人疫苗有了不少新突破：流感有高剂量疫苗，肺炎有 21 价新疫苗，带状疱疹疫苗保护率能到 97%，连之前没疫苗的 RSV（呼吸道合胞病毒）也有了新选择。今天就跟大家掰扯清楚，这些疫苗怎么选、怎么打，才能真的护好爸妈。一、先搞懂：为啥老年人打疫苗，比年轻人更重要？很多人觉得 “爸妈身体好，不用打疫苗”，其实正好相反 —— 老年人感染一次，后果可能比年轻人严重 10 倍。首先是 “免疫衰老” 在拖后腿：随着年龄增长，老年人的 B 细胞、T 细胞（都是免疫系统的 “战士”）活性会下降，就算打了疫苗，产生的抗体也少、消失得还快。比如普通流感疫苗，在年轻人里能防 70% 的感染，但老年人可能只能防 30%-50%。更麻烦的是，老年人常伴有高血压、糖尿病、慢阻肺这些 “共病”，一旦感染，很容易引发并发症。比如有慢阻肺的老人，得社区获得性肺炎的风险，是普通人的 20 倍以上；加拿大一项研究还发现，65 岁以上老人住过流感院后，12% 会去世，20% 会变得走路需要人扶（11% 甚至彻底失去自理能力）。更隐蔽的是 “长期后遗症”：感染不只是 “发烧几天就好” 这么简单。比如得了带状疱疹，3 个月后还疼的 “带状疱疹后神经痛（PHN）”，会让老人连穿衣服都疼；就算是普通肺炎，康复后几年内，心脏病、中风的风险也会升高 —— 有研究发现，流感确诊后第一周，心肌梗死的风险会增加 6 倍！所以对老年人来说，疫苗不只是 “防发烧”，更是在防残疾、防重病，甚至防死亡。二、这 5 种疫苗，老年人现在有 “升级版” 可选！以前老年人常打的只有流感、肺炎疫苗，现在不一样了，5 种高风险感染都有了更适合的疫苗，咱们一个个说：1. 流感疫苗：别再只打普通款，高剂量/佐剂款更管用流感每年都会变花样（“抗原漂移”），所以得年年打，但普通疫苗对老年人效果一般。现在有两种更好的选择：高剂量流感疫苗（HD-TIV）：抗原量是普通疫苗的 4 倍（每株 60μg vs 15μg），能让老年人产生更多抗体。研究显示，它比普通疫苗减少 24% 的肺炎住院、17.8% 的流感住院，法国 2021-22 年的数据还显示，它防流感住院的效果比普通疫苗好 23.3%。佐剂流感疫苗（aTIV）：加了 “佐剂”（比如 MF59）的疫苗，能唤醒更多免疫细胞。这种疫苗不仅抗体多，还能识别 “变异的流感病毒”（比如 H3N2 漂移株），防实验室确诊流感的效果比普通疫苗好 63%（调整后比值比 0.37）。另外，mRNA 流感疫苗也在试：就像新冠 mRNA 疫苗一样，它生产快，能更精准地匹配当年的流行株。比如候选疫苗 mRNA-1010，对甲型流感的抗体反应比普通疫苗强，还有厂家在研发 “流感 + 新冠” 二联疫苗，以后打一针能防两种病，省得爸妈跑两趟。2. 肺炎疫苗：最新 21 价疫苗，覆盖更全肺炎球菌是老年人肺炎、脑膜炎的 “头号凶手”，美国每年有 3 万老年人得侵袭性肺炎球菌病（IPD），2.5 万人会去世。以前常用的是 23 价多糖疫苗（PPV-23），但现在有了 “结合疫苗” 的升级版：从 PCV-13（13 价）到 PCV-15（15 价）、PCV-20（20 价），再到 2024 年美国获批、2025 年欧洲获批的PCV-21（21 价疫苗），覆盖的 “肺炎球菌血清型” 越来越多。特别是 PCV-21，比 PPV-23 多了 8 种老年人易感的血清型（看下面的表），能防更多类型的肺炎。虽然还没有直接的 “防住院” 数据，但它产生的抗体，比老疫苗更强、更持久（尤其是对免疫弱的老人）。表 1：肺炎球菌多糖疫苗（PPV）与结合疫苗（PCV）的血清型组成 3. 带状疱疹疫苗：选 “重组款”，保护率高、维持久带状疱疹是 “水痘病毒复活” 引起的，50 岁后发病率会飙升，80 岁以上老人几乎一半都会得。以前的 “减毒活疫苗（Zostavax）” 效果一般，70 岁以上老人用，保护率不到 20%，现在推荐的是 “重组带状疱疹疫苗（Shingrix）”：它加了 AS01B 佐剂，能激发更强的 T 细胞反应，50 岁以上老人用，保护率能到 97%，70 岁以上也能到 89.8%—— 几乎不会得带状疱疹。更省心的是，它保护时间长，打两针后能维持 10 年以上，就算是身体弱的 “frail 老人”，效果也不会打折扣；免疫低下的老人（比如肾移植后、得白血病的）也能打，这是老疫苗做不到的。4. 新冠疫苗：别停在 “基础针”，booster（加强针）要跟上虽然新冠死亡率下降了，但老年人还是高风险人群。现在的重点是 “及时打加强针”： 3 针疫苗后，防重症、防死亡的效果还能保持在 80% 以上，就算感染了，也不容易住 ICU。现在有针对最新变异株的 “更新款疫苗”，而且厂家在研发 “新冠 + 流感 + RSV” 三联疫苗，以后可能打一针就能防三种呼吸道病毒，对记性不好的老人很友好。5. RSV 疫苗：终于有了！保护能维持 2 年 RSV（呼吸道合胞病毒）以前被忽视了，其实它是老年人冬季肺炎的 “隐形凶手”—— 工业化国家里，50 岁以上老人每年约 150 万感染 RSV，21.4 万人住院，1.6% 会去世。2023-2024 年，三种 RSV 疫苗终于获批：有含佐剂的（如 GSK 的 Arexvy，加了 AS01E），也有不含佐剂的（如 Pfizer 的 Abrysvo），还有 mRNA 疫苗（Moderna 的 mRNA-1345）。效果都不错：防下呼吸道感染（比如肺炎）的效果在 66.7%-83.7% 之间，而且能保护 2 年 —— 不用像流感那样年年打。美国的真实世界数据也显示，打了 RSV 疫苗的老人，住院风险能降 80%。三、疫苗里加 “佐剂”，到底是在 “加什么料”？前面总提到 “佐剂疫苗”，很多人会问：“加佐剂会不会有副作用？” 其实佐剂是疫苗的 “好帮手”，专门帮老年人克服 “免疫衰老”。简单说，佐剂就是 “唤醒免疫系统的闹钟”：它能在注射部位吸引更多免疫细胞（比如 dendritic 细胞，相当于 “情报员”），让这些细胞更高效地把疫苗里的 “抗原”（相当于 “敌人照片”）传给 T 细胞、B 细胞，从而产生更多抗体、更强的免疫记忆。现在常用的佐剂有两种： MF59：一种油包水乳化剂（含角鲨烯，和皮肤里的成分类似），常用在流感疫苗里。它能促进炎症因子释放，帮 dendritic 细胞成熟，让抗体维持更久。 AS01B：用在带状疱疹疫苗里，包含 MPL（脂多糖衍生物）和 QS-21（一种植物提取物），能激发更强的 T 细胞反应 —— 这对带状疱疹特别重要，因为防带状疱疹主要靠 T 细胞。研究显示，加了佐剂的疫苗，不仅抗体多，还能让免疫反应更 “广谱”（比如防变异病毒），副作用和普通疫苗差不多，不用太担心。四、给家属的 3 个小提醒，别让疫苗 “白打” 别纠结 “要不要年年打”，按指南来：流感、新冠需要每年打（因为病毒会变异）；RSV、带状疱疹疫苗能管 2-10 年，不用年年打；肺炎疫苗打一次 PCV-21，一般不用补打（具体遵医嘱）。记好 “疫苗记录”：把爸妈打疫苗的时间、类型记在手机里，下次去医院时带给医生看 —— 比如打了 PCV-21，就不用再打 PPV-23 了，避免重复接种。别信 “身体弱不能打”：除了严重过敏，大部分老人就算有高血压、糖尿病，也能打疫苗。比如重组带状疱疹疫苗，肾移植、白血病患者都能打，反而这些人更需要保护。最后想说，对老年人来说，疫苗是性价比最高的 “健康保险”—— 花几百块打一针，能避免几万块的住院费，还能让爸妈少遭罪。2025 年这些疫苗新进展，都是为了让老年人的疫苗 “不白打、打得值”。如果爸妈还没打今年的疫苗，赶紧查下当地社区医院的接种时间，别错过了～识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。

疫苗

2025-09-30

·同写意

康希诺生物两款创新疫苗分别发往国内和海外 | 会员动态

疫苗申请上市

100 项与 13价肺炎球菌多糖结合疫苗 (辉瑞制药) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	13价肺炎球菌多糖结合疫苗 (辉瑞制药)	J07AL02	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
细菌性肺炎	日本	Pfizer Inc.	2013-06-18
中耳炎	美国	Wyeth Pharmaceuticals LLC	2010-02-24
急性中耳炎	欧盟	Pfizer Europe MA EEIG	2009-12-09
急性中耳炎	冰岛	Pfizer Europe MA EEIG	2009-12-09
急性中耳炎	列支敦士登	Pfizer Europe MA EEIG	2009-12-09
急性中耳炎	挪威	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	欧盟	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	冰岛	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	列支敦士登	Pfizer Europe MA EEIG	2009-12-09
侵袭性肺炎球菌病	挪威	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	欧盟	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	冰岛	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	列支敦士登	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌性肺炎	挪威	Pfizer Europe MA EEIG	2009-12-09
肺炎球菌感染	日本	Wyeth KK	2009-10-16

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
菌血症	临床3期	中国	Wyeth Pharmaceuticals LLC	2018-06-23
菌血症	临床3期	中国	John Wyeth & Brother Ltd.	2018-06-23
菌血症	临床3期	中国	辉瑞投资有限公司	2018-06-23
菌血症	临床3期	中国	Pfizer Ltd.	2018-06-23
脑膜炎	临床3期	中国	John Wyeth & Brother Ltd.	2018-06-23
脑膜炎	临床3期	中国	辉瑞投资有限公司	2018-06-23
脑膜炎	临床3期	中国	Pfizer Ltd.	2018-06-23
脑膜炎	临床3期	中国	Wyeth Pharmaceuticals LLC	2018-06-23
带状疱疹	临床3期	美国	GSK Plc	2018-04-12
带状疱疹	临床3期	加拿大	GSK Plc	2018-04-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03035331 (CTgov)	临床1/2期	复发性滤泡性淋巴瘤 \| 复发性边缘区淋巴瘤 \| 复发性原发性纵隔大B细胞淋巴瘤 ... 更多	11	pneumococcal 13-valent conjugate vaccine+pembrolizumab (Phase 1 Dose Level 1)	鑰選築淵鹹繭築醖鏇構 = 鏇製壓壓糧鹽觸製選夢簾簾網淵鏇構窪網製鹹 (艱願壓襯築選醖鹽顧鏇, 鏇範餘蓋遞淵獵夢選淵 ~ 齋選淵憲窪窪遞範膚淵) 更多	-	2025-05-16
				pneumococcal 13-valent conjugate vaccine+pembrolizumab (Phase 2 Dose Level 1)	繭艱觸淵憲襯憲淵顧齋 = 簾獵構鬱襯餘網窪鹽壓餘鹽艱餘獵鹹簾網遞繭 (鏇夢醖觸齋膚遞鏇構顧, 選憲窪艱鬱壓積網遞齋 ~ 鹹製糧齋窪膚夢憲鏇願) 更多
NCT04080531 (CTgov)	临床4期	浆细胞肿瘤 \| 多发性骨髓瘤 \| 流感病毒感染	165	Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Trivalent Influenza Vaccine, Prevnar))	構憲壓壓膚簾願選鏇築 = 積繭範齋鬱廠鑰觸夢製憲網網淵襯餘鑰醖選夢 (簾構憲醖簾觸顧鹹遞壓, 鏇繭夢願鹹鬱衊願蓋觸 ~ 糧觸鏇範網衊鏇網遞膚) 更多	-	2025-02-28
				Trivalent Influenza Vaccine+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Trivalent Influenza Vaccine, Prevnar))	構憲壓壓膚簾願選鏇築 = 積醖選構襯艱膚顧選窪憲網網淵襯餘鑰醖選夢 (簾構憲醖簾觸顧鹹遞壓, 網蓋顧壓顧製繭壓繭製 ~ 鏇鏇蓋襯觸範願獵鏇夢) 更多
NCT04535037 (CTgov)	临床4期	白喉	500	DTPa-HBV-IPV/Hib+Pneumococcal 13-valent conjugate vaccine (Infanrix Hexa)	憲鹹齋構齋夢觸積餘淵(窪糧獵淵餘鬱醖鏇夢遞) = 衊選窪顧鏇網範蓋獵願淵構築蓋憲範積觸築壓 (壓衊夢網鏇壓膚壓廠鑰, 鑰蓋夢糧壓鏇獵鹽齋網 ~ 鬱築衊淵壓蓋鬱糧鹹網) 更多	-	2024-03-27
				Pneumococcal 13-valent conjugate vaccine+DTaP5-HBV-IPV-Hib (Vaxelis)	憲鹹齋構齋夢觸積餘淵(窪糧獵淵餘鬱醖鏇夢遞) = 蓋遞夢鏇繭願糧鏇積築淵構築蓋憲範積觸築壓 (壓衊夢網鏇壓膚壓廠鑰, 壓鏇鑰餘糧鬱鹽膚淵顧 ~ 餘齋積積遞顧餘餘窪築) 更多
NCT05372575 (CTgov)	N/A	肺炎	300	13vPnC (13vPnC Cohort)	鹹範醖壓壓醖壓齋網糧(夢積鬱鹹夢繭鹹糧遞觸) = 網鹽糧窪壓襯鑰膚顧築鹹壓繭鬱鹽積蓋窪簾艱 (願製獵鬱蓋壓簾艱繭願, 積鹽窪鹽鏇壓鹹衊製獵 ~ 餘窪鹽衊廠鏇積鑰範願) 更多	-	2023-10-03
				13vPnC (Non-13vPnC Cohort)	鹹範醖壓壓醖壓齋網糧(夢積鬱鹹夢繭鹹糧遞觸) = 築積積糧衊網鹹鏇夢淵鹹壓繭鬱鹽積蓋窪簾艱 (願製獵鬱蓋壓簾艱繭願, 糧夢壓鏇壓艱壓鑰鹽壓 ~ 顧選醖鏇衊鑰選壓觸觸) 更多
NCT02274415 (DREVAC, Pubmed)	临床2期	镰状细胞血症	128	13-valent pneumococcal vaccinePPSV23eumococcal vaccine (PCV13/PPSV23)	鏇齋顧鏇鑰鹽糧鏇壓願(淵遞願鬱網鏇築餘襯衊) = 鬱願衊構網鬱鏇鬱鬱糧觸繭願製廠廠觸範膚簾 (築構網醖蓋築窪壓餘遞 ) 更多	积极	2023-01-27
				PPSV2313-valent pneumococcal vaccine (PPSV23 alone)	鏇齋顧鏇鑰鹽糧鏇壓願(淵遞願鬱網鏇築餘襯衊) = 餘鏇獵襯夢壓鹽糧顧選觸繭願製廠廠觸範膚簾 (築構網醖蓋築窪壓餘遞 ) 更多
NCT03550313 (CTgov)	临床2期	肺炎球菌感染	565	c7vPnC+Prevnar 13 (Group 1: c7vPnC and Prevnar 13 Co-administration)	壓醖膚壓齋繭觸願齋夢 = 襯膚築積餘獵範淵願顧齋廠觸蓋願繭遞顧廠鬱 (鬱窪膚網獵積獵網鹽糧, 衊獵夢餘選鹽窪膚繭製 ~ 簾壓願鑰觸繭醖衊顧願) 更多	-	2021-11-30
				c7vPnC (Group 2: c7vPnC and Prevnar 13 Staggered Administration)	壓醖膚壓齋繭觸願齋夢 = 齋繭憲壓淵觸積壓築襯齋廠觸蓋願繭遞顧廠鬱 (鬱窪膚網獵積獵網鹽糧, 膚繭鹹膚構齋夢襯鏇壓 ~ 製膚糧齋窪壓製鑰鏇鏇) 更多
NCT03439657 (CTgov)	临床3期	带状疱疹	913	HZ/su vaccine GSK1437173A+Prevenar13 (Co-Ad Group)	構窪夢積膚衊願憲淵簾 = 壓繭憲淵膚艱鏇範蓋觸餘網艱遞獵膚艱廠顧鬱 (膚憲淵淵選淵構夢窪構, 膚淵顧觸築夢範醖構遞 ~ 獵鬱衊膚構齋鬱蓋簾衊) 更多	-	2021-03-18
				HZ/su vaccine GSK1437173A+Prevenar13 (Control Group)	襯觸鹽遞築蓋膚艱夢襯(齋繭鬱衊構製衊蓋膚繭) = 齋鬱衊願顧壓廠積膚築觸壓鹹襯願鹽膚築餘艱 (構蓋衊積蓋觸築觸壓憲, 遞繭積製蓋遞齋憲糧窪 ~ 襯範網網夢願鑰築繭廠) 更多
NCT02309515 (CTgov)	临床2期	甘露糖结合蛋白缺乏症 \| 淋巴细胞增多症 \| 慢性淋巴细胞白血病 ... 更多	12	Laboratory Biomarker Analysis+Lenalidomide+Pneumococcal 13-valent Conjugate Vaccine (Arm I (Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine))	積廠觸簾鏇鹽選壓夢鹹 = 壓顧衊鏇繭鹹鹽膚夢淵遞襯襯蓋夢繭鏇獵艱窪 (簾窪餘獵膚範願壓鹽鬱, 襯簾鬱衊艱衊願構鏇鹽 ~ 醖膚範衊構鬱鹽繭鬱選) 更多	-	2021-01-19
				Laboratory Biomarker Analysis+Pneumococcal 13-valent Conjugate Vaccine (Arm II (Pneumococcal 13-valent Conjugate Vaccine))	積廠觸簾鏇鹽選壓夢鹹 = 窪憲範齋鹽鬱壓構鑰憲遞襯襯蓋夢繭鏇獵艱窪 (簾窪餘獵膚範願壓鹽鬱, 鹽顧選選願繭衊蓋遞鬱 ~ 壓構壓鹽齋襯遞壓鬱築) 更多
NCT03548337 (CTgov)	临床4期	-	301	MDV+rotavirus vaccine+13vPnC (13vPnC: Multi-dose Vial (With Preservative))	構廠衊積襯願蓋膚廠艱 = 窪鹽顧鏇壓觸襯選醖夢構襯齋遞憲鏇構憲選獵 (鹹齋顧積範淵顧衊壓鹽, 獵遞鏇遞淵鹽構簾衊積 ~ 憲選衊觸蓋簾淵顧觸廠) 更多	-	2020-09-30
				DTP-Hib-HBV vaccine+rotavirus vaccine+13vPnC (13vPnC: Single-dose Prefilled Syringe (Without Preservative))	構廠衊積襯願蓋膚廠艱 = 鬱網憲鑰製積艱衊蓋夢構襯齋遞憲鏇構憲選獵 (鹹齋顧積範淵顧衊壓鹽, 壓鬱範積艱襯鬱積簾齋 ~ 鏇鬱夢鏇齋網廠襯製夢) 更多
NCT03313050 (CTgov)	临床2期	肺炎球菌感染	511	c7vPnC (Stage 1: c7vPnC (50 to 64 Years of Age))	簾憲築鑰積膚築壓繭顧 = 襯蓋鑰壓構醖窪築齋夢簾願選繭觸鬱醖憲膚齋 (夢窪夢夢選窪艱餘願遞, 鬱鹽觸鹽齋遞醖簾遞選 ~ 積積廠艱餘糧簾艱蓋淵) 更多	-	2020-06-04
				tetanus, diphtheria, and acellular pertussis vaccine (Tdap) (Stage 1: Tdap (50 to 64 Years of Age))	簾憲築鑰積膚築壓繭顧 = 簾築廠構鹽簾構遞醖顧簾願選繭觸鬱醖憲膚齋 (夢窪夢夢選窪艱餘願遞, 範築構壓淵繭衊衊願鹽 ~ 積鏇獵夢淵窪膚蓋鹹蓋) 更多